HBW Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chattem purchase

This article was originally published in The Rose Sheet

Executive Summary

Johnson & Johnson's anti-cavity mouthwash brand ACT will be acquired by Chattem under an agreement in which the firm will pay $410 mil. in cash for five J&J and Pfizer Consumer Healthcare brands, Chattem announces Oct. 6. The transaction is subject to review and approval by the Federal Trade Commission and certain closing conditions, including J&J's acquisition of the Pfizer Consumer Healthcare division, which is expected to close by the end of the year (1"The Rose Sheet" July 3, 2006, p. 7). ACT would represent Chattem's first mouthwash brand; the firm also plans to acquire OTC brands Unisom, Cortizone, Kaopectate and Balmex. "These brands are responsive to advertising and can be extended with new products, which plays perfectly into our proven track record of growing brands through innovation and advertising," Chattem says. The pending transaction will be accretive to Chattem's earnings per share in 2007 and provides "excellent long-term growth opportunities for both sales and earnings," firm says...
Advertisement

Related Content

Chattem Sales Up 51% Behind Ongoing Push From J&J Acquisitions
Chattem completes acquisition
Gold Bond, Selsun Line Extensions To Help Drive Chattem’s 2007 Sales
J&J Acquires Listerine, Lubriderm As Part Of $16.6 Bil. Pfizer Deal
J&J Acquires Listerine, Lubriderm As Part Of $16.6 Bil. Pfizer Deal
Advertisement
UsernamePublicRestriction

Register

RS014259

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel